Trial Profile

A phase 2/3 trial of INZ-701 for the patients with ABCC6 Deficiency

Status: Planning

Phase of Trial: Phase II/III

Latest Information Update: 20 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

10 Jan 2025 According to an Inozyme Pharma media release, the company plans to initiate ASPIRE trial in early 2026,due to availability of financial resources, and ongoing regulatory review is pending.
10 Jan 2025 According to an Inozyme Pharma media release, the company is currently refining the study design to harmonize feedback from the FDA and EMA and it will continue regulatory engagement over the coming months to finalize the trial protocol.
06 Aug 2024 According to an Inozyme Pharma media release, initiation of this study in Q1 2025 is subject to regulatory review and sufficient funding.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com